Comparison of different LDL apheresis methods

References

• Bundesausschuss der Ärzte und Krankenkassen. Beschluss des Bundesausschusses der Ärzte und Krankenkassen über eine Änderung der Anlage A “Anerkannte Untersuchungs- und Behandlungsmethoden“ der Richtlinien über die Bewertung ärztlicher Untersuchungs- und Behandlungsmethoden gemäß § 135 Abs. 1 des Fünften Buches Sozialgesetzbuch (BUB-Richtlinien) [German reimbursement rules]. Deutsches Ärzteblatt100, 1595–1596 (2003).
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive summary US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute, 2001 May 28. Third report of the National Cholesterol Education Program (NCEP). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Jaeger BR, Bengel FM, Odaka K et al. Changes in myocardial vasoreactivity after drastic reduction of plasma fibrinogen and cholesterol: a clinical study in long-term heart transplant survivors using positron emission tomography. J. Heart Lung Transplant.24, 2022–2030 (2005).
   PubMed Web of Science ®Google Scholar
• Jaeger BR, Meiser B, Nagel D et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation96, II-154–158. (1997).
   Google Scholar
• Julius U, Parhofer KG, Heibges A, Kurz S, Klingel R, Geiss HC. Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis – comparison of performance characteristics with DALI and lipidfiltration. J. Clin. Apher.22, 215–223 (2007).
   PubMed Web of Science ®Google Scholar
• Otto C, Berster J, Otto B, Parhofer KG. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia. J. Clin. Apher.22, 301–305 (2007).
   PubMed Web of Science ®Google Scholar
• Opole IO, Belmont JM, Kumar A, Moriarty PM. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am. J. Cardiol.100, 1416–1418 (2007).
   PubMed Web of Science ®Google Scholar
• Keller C. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management. Ther. Apher. Dial.11, 2–8 (2007).
   PubMed Web of Science ®Google Scholar
• Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation95, 76–82 (1997).
   PubMed Web of Science ®Google Scholar
• Mellwig KP. Heparin-induced extracorporeal low-density lipoprotein precipitation. Therap. Apher. Dial.7, 365–369 (2003).
   PubMed Web of Science ®Google Scholar
• Mellwig KP, Baller D, Gleichmann U et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis139, 173–178 (1998).
   PubMed Web of Science ®Google Scholar
• Mellwig KP, van Buuren F, Schmidt HK, Wielepp P, Burchert W, Horstkotte D. Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment. Ther. Apher. Dial.10, 510–517 (2006).
   PubMed Web of Science ®Google Scholar
• Kizaki Y, Ueki Y, Yoshida K et al. Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease? Blood Coagul. Fibrinolysis10, 341–349 (1999).
   PubMed Web of Science ®Google Scholar
• Rubba P, Faccenda F, Di Somma S et al. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia. Stroke24, 1154–1161 (1993).
   PubMed Web of Science ®Google Scholar
• Kunz A, Gahn G, Hahn G, Hallmeyer-Elgner S, Julius U, Reichmann H. Cerebrovascular CO2 reactivity after DALI, HELP, and MDF apheresis. Am. Acad. Neurol. (2001).
   Google Scholar
• Utsumi K, Kawabe M, Hirama A et al. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. Clin. Chim. Acta377, 198–200 (2007).
   PubMed Web of Science ®Google Scholar
• Kobayashi S. Applications of LDL-apheresis in nephrology. Clin. Exp. Nephrol.12, 9–15 (2008).
   PubMed Web of Science ®Google Scholar
• Ramunni A, Quaranta N, Saliani MT, Fallacara RA, Ria R, Ranieri G. Does a reduction of adhesion molecules by LDL-apheresis have a role in the treatment of sudden hearing loss? Ther. Apher. Dial.10, 282–286 (2006).
   PubMed Web of Science ®Google Scholar
• Ramunni A, Ranieri G, Giancipoli G et al. Is the efficacy of LDL apheresis in ischemic optic neuropathy linked to a reduction in endothelial activation markers? Blood Purif.24, 405–412 (2006).
   PubMed Web of Science ®Google Scholar
• Yamane S, Matsugane T, Motohashi K et al. Double filtration plasmapheresis maintains normal adhesion molecule levels. Ther. Apher.2, 224–227 (1998).
   PubMedGoogle Scholar
• Richter V, Rassoul F, Reuter W et al. Effect of extracorporeal low-density lipoprotein elimination on circulating cell adhesion molecules in patients with hypercholesterolemia. Am. J. Cardiol.87, 1111–1113, A9. (2001).
   PubMed Web of Science ®Google Scholar
• Pulawski E, Mellwig KP, Brinkmann T, Kleesiek K, Horstkotte D. Influence of single low-density lipoprotein apheresis on the adhesion molecules soluble vascular cellular adhesion molecule-1, soluble intercellular adhesion molecule-1, and P-selectin. Ther. Apher.6, 229–233 (2002).
   PubMedGoogle Scholar
• Motohashi K, Yamane S. The effect of apheresis on adhesion molecules. Therap. Apher. Dial.7, 425–430 (2003).
   PubMed Web of Science ®Google Scholar
• Wang Y, Blessing F, Walli AK, Uberfuhr P, Fraunberger P, Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis175, 145–150 (2004).
   PubMed Web of Science ®Google Scholar
• Empen K, Otto C, Brodl UC, Parhofer KG. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J. Clin. Apheresis17, 38–43 (2002).
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Gibson CA. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Am. J. Cardiol.95, 1246–1247 (2005).
   PubMed Web of Science ®Google Scholar
• Tsuchida H, Shigematsu H, Ishimaru S, Iwai T, Akaba N, Umezu S. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Int. Angiol.25, 287–292 (2006).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Sato Y, Niizuma S et al. Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms. J. Clin. Apher.22, 287–291 (2007).
   PubMed Web of Science ®Google Scholar
• Julius U, Siegert G, Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int. J. Artif. Organs23, 199–206 (2000).
   PubMed Web of Science ®Google Scholar
• Kojima S, Harada-Shiba M, Toyota Y et al. Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int. J. Artif. Organs15, 185–190 (1992).
   PubMed Web of Science ®Google Scholar
• Kojima S, Harada-Shiba M, Yamamoto A. Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column. Ther. Apher.1, 309–313 (1997).
   PubMedGoogle Scholar
• Corrado E, Novo S. Evaluation of C-reactive protein in primary and secondary prevention. J. Investig. Med.55, 430–438 (2007).
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Moriya H, Maesato K, Okamoto K, Ohtake T. LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J. Clin. Apher.20, 239–243 (2005).
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Oka M, Moriya H, Maesato K, Okamoto K, Ohtake T. LDL-apheresis reduces P-Selectin, CRP and fibrinogen – possible important implications for improving atherosclerosis. Ther. Apher. Dial.10, 219–223 (2006).
   PubMed Web of Science ®Google Scholar
• Schettler V, Wieland E. [Effects of LDL-apheresis – more than reduction of cholesterol?] Dtsch Med. Wochenschr.132, 575–578 (2007).
   PubMed Web of Science ®Google Scholar
• Otto C, Geiss HC, Empen K, Parhofer KG. Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis174, 151–156 (2004).
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Gibson CA, Shih J, Matias MS. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis158, 495–498 (2001).
   PubMed Web of Science ®Google Scholar
• Wieland E, Schettler V, Armstrong VW. Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. Atherosclerosis162, 187–191 (2002).
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Katsube S, Shimoda M et al. Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clin. Chim. Acta321, 107–112 (2002).
   PubMed Web of Science ®Google Scholar
• Kojima S, Shida M, Yokoyama H. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Therap. Apher. Dial.7, 431–434 (2003).
   PubMed Web of Science ®Google Scholar
• Kopprasch S, Julius U, Gromeier S, Kuhne H, Graessler J. Distinct effects of LDL apheresis by hemoperfusion (DALI) and heparin-induced extracorporeal precipitation (HELP) on leukocyte respiratory burst activity of patients with familial hypercholesterolemia. J. Clin. Apheresis15, 249–255 (2000).
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Di Giacomo S, Vivenzio A et al. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clin. Sci. (Lond.)100, 191–198 (2001).
   PubMed Web of Science ®Google Scholar
• Hahnel D, Thiery J, Brosche T, Engelmann B. Role of plasmalogens in the enhanced resistance of LDL to copper-induced oxidation after LDL apheresis. Arterioscler. Thromb. Vasc. Biol.19, 2431–2438 (1999).
   PubMed Web of Science ®Google Scholar
• Donner MG, Parhofer KG, Richter WO, Schwandt P. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis. Metabolism48, 881–886 (1999).
   PubMed Web of Science ®Google Scholar
• Inoue I, Takahashi K, Kikuchi C, Katayama S. LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patient with hemodialysis treatment. Diabetes Care19, 1103–1107 (1996).
   PubMed Web of Science ®Google Scholar
• Schuff-Werner P, Schettler V. Plaque stabilization by LDL apheresis? Herz24, 57–61 (1999).
   PubMed Web of Science ®Google Scholar
• Pulawski E, Mellwig KP, Horstkotte D. H.E.L.P. apheresis and oxidative stress. Z. Kardiol.92, III38–III41 (2003).
   PubMedGoogle Scholar
• Blaha M, Cermanova M, Blaha V et al. Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. Ther. Apher. Dial.11, 9–15 (2007).
   PubMed Web of Science ®Google Scholar
• Krieter DH, Steinke J, Kerkhoff M et al. Contact activation in low-density lipoprotein apheresis systems. Artif. Organs29, 47–52 (2005).
   PubMed Web of Science ®Google Scholar
• Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis189, 31–38 (2006).
   PubMed Web of Science ®Google Scholar
• Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol.82, 1489–1495 (1998).
   PubMed Web of Science ®Google Scholar
• Jaeger BR. The HELP system for the treatment of atherothrombotic disorders: a review. Therap. Apher. Dial.7, 391–396 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon BR, Kelsey SF, Dau PC et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am. J. Cardiol.81, 407–411 (1998).
   PubMed Web of Science ®Google Scholar
• Schuff-Werner P, Gohlke H, Bartmann U et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur. J. Clin. Invest.24, 724–732 (1994).
   PubMed Web of Science ®Google Scholar
• Nishimura S, Sekiguchi M, Kano T et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis144, 409–417 (1999).
   PubMed Web of Science ®Google Scholar
• Richter WO, Donner MG, Hofling B, Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism47, 863–868 (1998).
   PubMed Web of Science ®Google Scholar
• Kanemitsu S, Tekekoshi N, Murakami E. Effects of LDL apheresis on restenosis after angioplasty. Chem. Phys. Lipids67–68, 339–343 (1994).
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Niwa A, Sinoda T. State of percutaneous transluminal coronary artery angioplasty and effectiveness of low-density lipoprotein apheresis. Ther. Apher.5, 226–231 (2001).
   PubMedGoogle Scholar
• Blessing F, Jaeger BR, Oberhoffer M, Reichart B, Seidel D. Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses). Z. Kardiol.92, III42–III7 (2003).
   PubMedGoogle Scholar
• Shuhaiber JH, Evans AN, Massad MG, Geha AS. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur. J. Cardio-thorac. Surg.22, 387–396 (2002).
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Harada-Shiba M, Kawaguchi A, Tsushima M. Apheresis technology for prevention and regression of atherosclerosis. Ther. Apher.5, 221–225 (2001).
   PubMedGoogle Scholar
• Masaki N, Tatami R, Kumamoto T et al. Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy. Int. Heart J.46, 833–843 (2005).
   PubMed Web of Science ®Google Scholar
• Krebs A, Krebs K, Keller F. Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001. Int. J. Artif. Organs27, 137–148 (2004).
   PubMed Web of Science ®Google Scholar